Scholar Rock Holding Net Income Growth & History (SRRK)
Scholar Rock Holding's net income was −$377.9M for fiscal 2025.
View full Scholar Rock Holding company overviewScholar Rock Holding annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$377.9M | −$131.6M | — |
| 2024 | 2024-12-31 | −$246.3M | −$80.5M | — |
| 2023 | 2023-12-31 | −$165.8M | −$31.3M | — |
| 2022 | 2022-12-31 | −$134.5M | −$2.7M | — |
| 2021 | 2021-12-31 | −$131.8M | −$45.3M | — |
| 2020 | 2020-12-31 | −$86.5M | −$35.5M | — |
| 2019 | 2019-12-31 | −$51.0M | −$1.7M | — |
| 2018 | 2018-12-31 | −$49.3M | −$24.3M | — |
| 2017 | 2017-12-31 | −$25.0M | — | — |
Scholar Rock Holding quarterly net income
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$109.9M | $135,000 | — |
| Q1 2026 | 2026-03-31 | −$105.5M | −$30.8M | — |
| Q4 2025 | 2025-12-31 | −$91.0M | −$24.5M | — |
| Q3 2025 | 2025-09-30 | −$102.2M | −$37.7M | — |
| Q2 2025 | 2025-06-30 | −$110.0M | −$51.5M | — |
| Q1 2025 | 2025-03-31 | −$74.7M | −$17.9M | — |
| Q4 2024 | 2024-12-31 | −$66.5M | −$20.3M | — |
| Q3 2024 | 2024-09-30 | −$64.5M | −$22.1M | — |
| Q2 2024 | 2024-06-30 | −$58.5M | −$20.6M | — |
| Q1 2024 | 2024-03-31 | −$56.9M | −$17.5M | — |
| Q4 2023 | 2023-12-31 | −$46.1M | −$6.9M | — |
| Q3 2023 | 2023-09-30 | −$42.4M | $938,000 | — |
| Q2 2023 | 2023-06-30 | −$37.9M | $6.1M | — |
| Q1 2023 | 2023-03-31 | −$39.4M | −$31.4M | — |
| Q4 2022 | 2022-12-31 | −$39.3M | −$3.3M | — |
| Q3 2022 | 2022-09-30 | −$43.3M | −$5.8M | — |
| Q2 2022 | 2022-06-30 | −$44.0M | −$13.3M | — |
| Q1 2022 | 2022-03-31 | −$8.0M | $19.7M | — |
| Q4 2021 | 2021-12-31 | −$35.9M | −$9.3M | — |
| Q3 2021 | 2021-09-30 | −$37.5M | −$13.9M | — |
| Q2 2021 | 2021-06-30 | −$30.7M | −$11.4M | — |
| Q1 2021 | 2021-03-31 | −$27.7M | −$10.6M | — |
| Q4 2020 | 2020-12-31 | −$26.6M | −$15.0M | — |
| Q3 2020 | 2020-09-30 | −$23.6M | −$7.4M | — |
| Q2 2020 | 2020-06-30 | −$19.3M | −$6.8M | — |
| Q1 2020 | 2020-03-31 | −$17.1M | −$6.3M | — |
| Q4 2019 | 2019-12-31 | −$11.6M | $3.4M | — |
| Q3 2019 | 2019-09-30 | −$16.1M | −$5.4M | — |
| Q2 2019 | 2019-06-30 | −$12.5M | $2.2M | — |
| Q1 2019 | 2019-03-31 | −$10.8M | −$1.9M | — |
| Q4 2018 | 2018-12-31 | −$15.0M | — | — |
| Q3 2018 | 2018-09-30 | −$10.8M | −$4.8M | — |
| Q2 2018 | 2018-06-30 | −$14.7M | −$8.8M | — |
| Q1 2018 | 2018-03-31 | −$8.9M | — | — |
| Q3 2017 | 2017-09-30 | −$5.9M | — | — |
| Q2 2017 | 2017-06-30 | −$5.9M | — | — |
Scholar Rock Holding net income trends
Over the last five fiscal years, Scholar Rock Holding's net income decreased from −$86.5M to −$377.9M, a change of −$291.5M. The latest reported quarter, Q2 2026, shows −$109.9M.
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Scholar Rock Holding source filings ↗Community posts
Scholar Rock wins FDA approval for muscle-targeted SMA treatment
Scholar Rock ($SRRK) received FDA approval for ISEMBYLD, its apitegromab treatment for spinal muscular atrophy, in patients aged two and older receiving SMN2-targeted therapy. The company plans to begin shipping the medicine within days. Th ...